Pilot RECAP Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions
Psychedelic ExperiencesAmnesia
Interventions
DRUG

Psilocybin and Midazolam

"The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.~The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight."

Trial Locations (1)

53792

UWHealth, 600 Highland Avenue, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER